Brain and Cognition Discovery Foundation (BCDF)

Developing novel innovative strategies capable of augmenting best practices in today's healthcare ecosystem.

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

Big news!!! We are recruiting adults with MDD for an open-label neuroimaging study with a novel and rapid-acting antidepressant, Dextromethorphan-Bupropion 🧠💡If you or someone you know is interested, please email our team at ✉️[email protected]

https://t.co/QyYgnm5mOI

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

The BCDF is recruiting participants for KOASTAL-2, a clinical study happening in Toronto and Mississauga.

Individuals diagnosed with major depressive disorder and are 18 to 65 years old may be eligible for this study.

Reach out to us at [email protected] to learn more!

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

KOASTAL-2 is assessing a new once-daily treatment called Navacaprant for depression and anhedonia in adults!

Individuals diagnosed with major depressive disorder and are 18 to 65 years old may be eligible for this study.

Interested? Email us at [email protected]

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

The KOASTAL-2 study taking place in Toronto and Mississauga is assessing Navacaprant for the treatment of depressive symptoms and anhedonia in adults (18 to 65 years old) with major depressive disorder.

Have questions? If so, please reach out to us at [email protected]

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

A new once-daily treatment called Navacaprant is being evaluated in adults (18 - 65 years old) with major depressive disorder.

For more information, visit our website at: https://t.co/WOUZMNbGkV

Have any questions? Please reach out to us at [email protected]

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

The KOASTAL-2 study is evaluating a new once-daily treatment called Navacaprant on depressive symptoms and anhedonia in adults with major depressive disorder.

To learn more about this study, visit: https://t.co/WOUZMNbGkV

Have any questions? Email us at: [email protected]

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

KOASTAL-2 is a clinical study taking place in Toronto and Mississauga. This study aims to evaluate a new once-daily treatment called Navacaprant for adults with major depressive disorder.

To participate or learn more, please reach out to us at [email protected]

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

KOASTAL-2 is investigating a once-daily medicine called Navacaprant for the treatment of depressive symptoms and anhedonia in adults with major depressive disorder.

To learn more, visit: https://t.co/WOUZMNb8vn

For inquiries, please email us at [email protected]

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

The KOASTAL-2 study is taking place in Toronto/Mississauga and aims to evaluate a once-daily treatment called Navacaprant for adults with depression.

To learn more about the study, visit: https://t.co/WOUZMNbGkV

Have any questions? Please email us at [email protected]

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

The KOASTAL-2 study is evaluating the use of a once-daily treatment called Navacaprant in adults with major depressive disorder.

To learn more about the study, visit our website at: https://t.co/kKpZSvWH4m

Have any questions? Feel free to email us at [email protected]

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

The KOASTAL-2 study is evaluating a once-daily treatment called Navacaprant for its use in adults with major depressive disorder.

To learn more about KOASTAL-2, visit https://t.co/WOUZMNb8vn

Have questions about the study? Reach out to us at [email protected]

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

The KOASTAL-2 study is investigating a once-daily treatment called Navacaprant for depressive symptoms and anhedonia (reduced joy or pleasure in most, if not all activities) in adults with major depressive disorder.

To learn more about this study, visit https://t.co/WOUZMNb8vn

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

The KOASTAL-2 study is investigating Navacaprant for the treatment of depression and anhedonia (reduced joy or pleasure in activities) in adults.

To learn more, visit our website at
https://t.co/WOUZMNb8vn

Have questions? Feel free to email us at [email protected]

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

KOASTAL-2 is evaluating Navacaprant as a new treatment for depressive symptoms and anhedonia in adults with major depressive disorder.

To learn more about the study, visit our website at https://t.co/WOUZMNbGkV

Have any questions? Reach out to us at [email protected]

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

The KOASTAL-2 study is looking at Navacaprant as a treatment for depressive symptoms and anhedonia in adults with major depressive disorder.

To learn more about KOASTAL-2, visit https://t.co/WOUZMNb8vn

Have questions about the study? Reach out to us at [email protected]

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

The KOASTAL-2 study is evaluating Navacaprant as a treatment for depressive symptoms and anhedonia in adults with major depressive disorder.

Want to know more? Visit our website at https://t.co/WOUZMNb8vn

Have questions? Reach out to us at [email protected]

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

The KOASTAL-2 study is evaluating Navacaprant as a new treatment for adults with major depressive disorder.

To learn more about KOASTAL-2, visit https://t.co/WOUZMNb8vn

Have questions about KOASTAL-2? Reach out to us at [email protected]

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

The KOASTAL-2 study is evaluating a new treatment called Navacaprant on depressive symptoms and anhedonia in adults with major depressive disorder.

To learn more, visit: https://t.co/WOUZMNb8vn

Have questions? Email us at: [email protected]

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

KOASTAL-2 is evaluating Navacaprant for the treatment of depressive symptoms and anhedonia (reduced joy or pleasure in activities) in adults with major depressive disorder.

Interested or have questions about the study? Feel free to reach out to us at [email protected]

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

The BCDF is recruiting participants for KOASTAL-2, a clinical study evaluating a new treatment called Navacaprant for the treatment of depression and anhedonia.

Have questions about the study? Feel free to reach out to us at [email protected]